With Moderna and BioNTech offering a model — in the US and Europe, respectively — for how mRNA biotechs can enjoy a meteoric rise to profit and fame with just one successful Covid-19 vaccine, a…
In TV commercials, music can trigger an emotion, establish a jingle or simply act as a background sound layer. In pharma ads, subtle background music is particularly common because by FDA rules music…
When Mylan and Pfizer’s Upjohn unit merged last year, headlines touted the $12 billion deal and newly named Viatris as the largest generic drugmaker in the world. But that’s not exactly how the…
The FDA’s Oncologic Drugs Advisory Committee has decided to cancel a planned meeting on Thursday to discuss two cancer drugs that previously won accelerated approvals but failed to confirm clinical…
After years as the top spending pharma TV advertiser, AbbVie’s Humira brand finally downshifted earlier this year, ceding much of its marketing budget to up-and-coming sibling meds Skyrizi and Rinvoq.…
Sciwind Biosciences announced last night that it signed an expansive license agreement with Sanofi to develop and commercialize Sanofi’s long-lasting glucose-dependent insulinotropic polypeptide (GIP)…
In another setback for Biogen, the big biotech lost its appeal to revive a patent for the once-blockbuster drug Tecfidera, marking a likely conclusion to the case. The US Court of Appeals for the…
When ImmunoGen’s lead antibody-drug conjugate flunked a Phase III study in ovarian cancer a couple years ago, the company clung to hope that it would perform better in a subgroup of patients with high…
TG Therapeutics took a hit Tuesday morning after announcing the FDA will convene an adcomm ahead of the biotech’s upcoming PDUFA date for a blood cancer combo therapy, throwing a potential decision…
Olema Oncology had been preparing to present the first clinical data from its lead program at a conference next week, but the biotech’s poster supposedly leaked online Monday. In response, Olema…
